Multicomponent, Tumor-Homing Chitosan Nanoparticles for Cancer Imaging and Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Key, Jaehong | - |
dc.contributor.author | Park, Kyeongsoon | - |
dc.date.available | 2019-03-08T09:36:17Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4717 | - |
dc.description.abstract | Current clinical methods for cancer diagnosis and therapy have limitations, although survival periods are increasing as medical technologies develop. In most cancer cases, patient survival is closely related to cancer stage. Late-stage cancer after metastasis is very challenging to cure because current surgical removal of cancer is not precise enough and significantly affects bystander normal tissues. Moreover, the subsequent chemotherapy and radiation therapy affect not only malignant tumors, but also healthy tissues. Nanotechnologies for cancer treatment have the clear objective of solving these issues. Nanoparticles have been developed to more accurately differentiate early-stage malignant tumors and to treat only the tumors while dramatically minimizing side effects. In this review, we focus on recent chitosan-based nanoparticles developed with the goal of accurate cancer imaging and effective treatment. Regarding imaging applications, we review optical and magnetic resonance cancer imaging in particular. Regarding cancer treatments, we review various therapeutic methods that use chitosan-based nanoparticles, including chemo-, gene, photothermal, photodynamic and magnetic therapies. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Multicomponent, Tumor-Homing Chitosan Nanoparticles for Cancer Imaging and Therapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/ijms18030594 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.18, no.3 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000396253700125 | - |
dc.identifier.scopusid | 2-s2.0-85014830059 | - |
dc.citation.number | 3 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 18 | - |
dc.type.docType | Review | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | chitosan | - |
dc.subject.keywordAuthor | nanoparticles | - |
dc.subject.keywordAuthor | drug delivery | - |
dc.subject.keywordAuthor | optical imaging | - |
dc.subject.keywordAuthor | magnetic resonance imaging | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | gene therapy | - |
dc.subject.keywordAuthor | photothermal therapy | - |
dc.subject.keywordAuthor | photodynamic therapy | - |
dc.subject.keywordAuthor | hyperthermic therapy | - |
dc.subject.keywordPlus | IRON-OXIDE NANOPARTICLES | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | MULTIFUNCTIONAL NANOPARTICLES | - |
dc.subject.keywordPlus | POLYMERIC NANOCONSTRUCTS | - |
dc.subject.keywordPlus | GOLD NANORODS | - |
dc.subject.keywordPlus | GENE-THERAPY | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | SIRNA | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.